[4-(1,3,4-oxadiazol-2-yl)phenyl]boronic Acid → Isobutyl 2-(4-(1,3,4-oxadiazol-2-yl)phenyl)pyridin-3-ylsulfonyl(3-methoxy-5-methylpyrazin-2-yl)carbamate
Reaktionsgleichung
[O:1]1[CH:5]=[N:4][N:3]=[C:2]1[C:6]1[CH:11]=[CH:10][C:9](B(O)O)=[CH:8][CH:7]=1.[CH2:15]([O:19][C:20]([N:22]([C:33]1[C:38]([O:39][CH3:40])=[N:37][C:36]([CH3:41])=[CH:35][N:34]=1)[S:23]([C:26]1[C:27](Cl)=[N:28][CH:29]=[CH:30][CH:31]=1)(=[O:25])=[O:24])=[O:21])[CH:16]([CH3:18])[CH3:17]>>[CH2:15]([O:19][C:20]([N:22]([C:33]1[C:38]([O:39][CH3:40])=[N:37][C:36]([CH3:41])=[CH:35][N:34]=1)[S:23]([C:26]1[C:27]([C:9]2[CH:10]=[CH:11][C:6]([C:2]3[O:1][CH:5]=[N:4][N:3]=3)=[CH:7][CH:8]=2)=[N:28][CH:29]=[CH:30][CH:31]=1)(=[O:25])=[O:24])=[O:21])[CH:16]([CH3:18])[CH3:17]Komponenten
3
Versuchsvorschrift
In this aspect of the invention [4-(1,3,4-oxadiazol-2-yl)phenyl]boronic acid is coupled with N-(isobutoxycarbonyl)-2-chloro-N-(3-methoxy-5-methylpyrazin -2-yl)pyridine-3-sulphonamide to form N-(isobutoxycarbonyl) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide.